 |
 |
 |
|
Pharmacokinetics of ABT-450/r and ABT-267 in Treatment-Experienced HCV Subgenotype 1b- and Genotype 2-Infected Japanese Subjects
|
|
|
Reported by Jules Levin
Asian Pacific Association for The Study of the Liver, Brisbane (APASL -2014)
Presenter: Prajakta Badri
14 March 2014
Authors: P Badri, S Dutta, L Rodrigues Jr. ,
RA Vilchez, B Bernstein, R Menon
AbbVie, Global Pharmaceutical R&D, North Chicago, IL, USA







|
|
|
 |
 |
|
|